Erlonat belongs to a class of medications called Kinase inhibitors and contains erlotinib. It is used for the treatment of non-small cell lung cancer and in combination with Gemcitabine, is used for the treatment of pancreatic cancer which spreads to adjacent tissues of the body. The action mechanism of the medicine is as follows:
Functions by blocking the action of an abnormal protein to slow down the growth of cancer cells
Usually 150 mg tablet is administered, at least an hour before or two hours after the ingestion of food, for curing pancreatic non-small cell lung cancer. Erlonat is usually given as 100 mg tablets, at least an hour before or two hours after the intake of food, for curing of pancreatic cancer, in combination with gemcitabine.
Symptoms of overdose may include diarrhea and rash
The medicine should not be taken without consulting the doctor if the patient has liver disease, lung or breathing problems (other than lung cancer).
Do not take aspirin, or products containing aspirin, unless prescribed by the doctor Patient must take Erlonat at substantial time gap, if antacids are also being taken If the patient is allergic to the medicine or any of its constituents, then intake is not suggestible
Erlonat consumption should avoided if the patient is pregnant or breast feeding the child. Doctor consultation suggested for use of birth control during treatment with Erlonat. It is not yet established whether Erlonat passes into breast milk or not.